Drug Database
TE

testosterone (testosterone, Acrux / LY900011 / Axiron)

✓ Approved

Eli Lilly · AR · Steroids

What is testosterone?

testosterone is a steroids developed by Eli Lilly. It is approved for therapeutic indications via topical or transdermal.

Drug Profile

Brand Namestestosterone, Acrux, LY900011, Axiron
CompanyEli Lilly
Drug ClassSteroids, Small Molecule
Molecular TargetAR
RouteTopical, Transdermal
StatusApproved

Mechanism of Action

Molecular Targets

testosterone acts on 1 molecular target:

ARandrogen receptor (DHTR, AR8)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

testosterone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Endocrine disordersHypogonadism✓ Approved

Related Research Articles

PubMedRoyal Society open science2026-11-11

Distinct space-use patterns are associated with alternative reproductive tactics in lekking ruffs Calidris pugnax.

Spezie Giovanni G, Dinya Gergely G, Gelencsér-Horváth Anna A, Goymann Wolfgang W et al.

Territoriality is a key strategy through which animals secure access to reproductive opportunities, yet in many lekking species, males differ in their investment in defending space. Breeding aggregations often include territorial residents and non-territorial floaters, raising questions about the flexibility and endocrine regulation of alternative spatial tactics. The ruff (Calidris pugnax) provides a powerful model to address these questions because males occur as three genetically determined reproductive morphs: territorial independents and two non-territorial floater morphs, satellites and faeders. Using artificial intelligence-assisted tracking in a captive colony, we quantified fine-scale space-use patterns within experimental and control leks. Our aim was to test whether male morphs adjust spatial behaviour when social opportunities arise. Independents exhibited smaller and more segregated activity areas, whereas satellites and faeders showed larger, overlapping activity areas, consistent with a floater strategy. Despite experimentally manipulating lek composition to create single-morph social environments, neither satellites nor faeders adopted territorial-like spatial behaviour. In addition, circulating concentrations of testosterone were higher in independents than faeders and satellites, but short-term variation in testosterone was not linked to changes in spatial behaviour and experimental treatment. These findings support the view that space-use tactics in ruffs represent fixed specializations rather than flexible responses to social opportunities.

PubMedFrontiers in sports and active living2026-11-11

Effects of eight weeks of functional training with blood flow restriction on biochemical, cognitive, and functional outcomes in postmenopausal women: protocol for a single-blind randomized controlled trial.

Shakoor Elham E, Aliakbari Jam Faezeh F, Khafaei Mostafa M, Carneiro Lara L et al.

Aging in women is accompanied by impaired muscle and cognitive function, reduced anabolic activity, and chronic low-grade inflammation. Blood flow restriction (BFR) may enhance adaptations to low-load exercise, but its effects when combined with functional training in postmenopausal women are unclear. This trial will examine the effects of eight weeks of functional training with BFR on biochemical, cognitive, and functional outcomes in postmenopausal women. This protocol describes a single-blind, assessor-masked, randomized controlled trial that will recruit 45 eligible postmenopausal women, defined as having experienced no menstrual bleeding for at least 24 consecutive months before screening, without another identifiable physiological or pathological cause. After health screening and physician-confirmed examination, participants will be randomly assigned (1:1:1) to functional training with BFR (FTBFR; n = 15), functional training alone (FT; n = 15), or non-exercise control (CON; n = 15) using web-based randomization. Exercise groups will complete supervised sessions three times weekly for eight weeks. Primary outcomes are plasma/serum concentrations of growth hormone, insulin-like growth factor-binding protein-3, interleukin-6, C-reactive protein, vascular endothelial growth factor, testosterone, and cortisol, measured by ELISA; the testosterone-to-cortisol ratio will also be calculated. Cognitive outcomes include the Mini-Mental State Examination, Montreal Cognitive Assessment, Stroop test, and Corsi block-tapping test. Secondary outcomes are handgrip strength, upper- and lower-body muscle strength, Timed Up and Go five-times-sit-to-stand performance, quality of life (SF-36), and pain. This trial will clarify whether adding BFR to functional training provides additional biochemical, cognitive, and functional benefits in Postmenopausal women and may inform safe, low-intensity exercise strategies for healthy aging. https://en.irct.ir/trial/89951, IRCT20191123045478N4.

PubMedJournal of medical case reports2026-11-11

Pituitary stalk interruption syndrome: a case report.

Biswas Som S

Pituitary stalk interruption syndrome (PSIS) is a rare congenital disorder characterized by an interrupted or absent pituitary stalk, ectopic posterior pituitary, and anterior pituitary hypoplasia, resulting in varying degrees of hypopituitarism. An 18-year-old white American male with a history of panhypopituitarism, adrenal insufficiency, and Asperger's syndrome presented with seizures. Examination revealed short stature and absent secondary sexual characteristics. Endocrine evaluation demonstrated multiple pituitary hormone deficiencies. Magnetic resonance imaging showed a hypoplastic anterior pituitary gland, ectopic posterior pituitary, and absent pituitary stalk, confirming the diagnosis of PSIS. Hormone replacement therapy with hydrocortisone, levothyroxine, growth hormone, and testosterone enanthate was initiated. PSIS should be considered in patients with growth failure, delayed puberty, and multiple pituitary hormone deficiencies. Early recognition and timely hormone replacement are critical to optimize growth, pubertal development, and long-term outcomes.

PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Changes of age-related androgen and their significance in males].

Wei Nini N, Yuan Shuning S, Yang Xiaoyu X, Cui Yugui Y

In different age stages of males, androgen levels exhibit unique changing patterns. During the fetal period, high levels of androgen promote sexual differentiation and initial development of male reproductive organs. In puberty, sustained and gradual androgen secretion drives the development of secondary sexual characteristics and maturation of the reproductive system. Adulthood is characterized by abundant androgen synthesis and secretion, which ensures sexual function and spermatogenesis. As men enter middle and old age, the level of androgen continuously declines due to changes in testicular microenvironment, potentially leading to late-onset hypogonadism. These characteristic physiological fluctuations of androgen levels across different life stages serve as the primary driving force for male reproductive system development, secondary sexual characteristics, spermatogenic function, and sexual function, while also being closely associated with musculoskeletal, metabolic, and cardiovascular systems. Testosterone replacement therapy and antioxidant therapy provide effective means to address androgen deficiency. This paper elaborates on androgen changes and their physiological significance across different male age stages, and explores clinical treatments and novel approaches for androgen deficiency.

PubMedFrontiers in endocrinology2026-11-11

The improvement effect of androgen priming on fertility in patients with diminished ovarian reserve and its impact on in vitro fertilization outcomes: a systematic review and meta-analysis.

Li Xuanling X, Sui Chenlin C, Zhang Baofang B, Bai Yuquan Y et al.

Evaluate the effect of using androgen supplements (including transdermal testosterone gel and dehydroepiandrosterone (DHEA)) to priming androgens in the body and improve fertility in patients with diminished ovarian reserve (DOR). Electronic searches were conducted on seven databases, including Scopus, Web of Science, PubMed, Springer, VIP Information, Wanfang, and China National Knowledge Infrastructure (CNKI), to search for studies published as of July 5, 2026. Randomized controlled trails (RCTs) and non-randomized controlled trails of using androgen supplements (i.e. dehydroepiandrosterone (DHEA) and transdermal testosterone gel (TTG)) to intervene in improving fertility and IVF outcomes in patients with DOR were embodied. The study applied systematic review and meta-analysis methods to systematically summarize the main outcome measures, including FSH, AMH, AFC, retrieved oocytes, and clinical pregnancy rate. In addition, indicators such as the number of fertilized embryos, top-quality day-3 embryos, live birth rate and miscarriage rate were also evaluated. The meta-analysis included 14 studies with 2132 participants. Analyses of RCTs and non-randomized controlled trials were conducted separately. A comprehensive analysis of existing evidence indicated that androgen supplementation, including DHEA and TTG, can improve count of retrieved oocytes [RCTs (MD = 0.79, 95% CI [0.50,1.09], p<0.00001)]. A retrospective analysis of non-randomized controlled trials showed that androgen supplementation can significantly increase the number of Top-quality day-3 embryos (MD 0.47, [95% CI: [0.28, 0.66], p < 0.00001), the count of fertilized embryos (MD 0.78, [95% CI: [0.49, 1.06], p < 0.00001), and clinical pregnancy rate (OR = 2.23, 95% CI [1.49,3.36], p = 0.0001). Besides, androgen supplementation showed Intervention with androgen supplements for 2 months was beneficial for retrieving more oocytes (p < 0.05) through the results in RCT. And also showed a more significant improvement in retrieved oocytes and metaphase II oocytes in DOR patients with an average age of over 40 years (p < 0.05). The subgroup analysis results indicated that the application of GnRH antagonists as IVF stimulation protocol was more beneficial in increasing the number of retrieved oocytes than the adopt of GnRH agonists.The sensitivity analysis concludes that our conclusion is robust. Androgen priming (including DHEA and TTG) may be beneficial for improving the fertility of DOR patients undergoing IVF, enhancing their ovarian response, mainly manifested as an increase in oocyte retrieval. However, whether this therapy can improve the clinical pregnancy rate and other outcome indicators of DOR women undergoing in vitro fertilization remains to be further determined by more randomized controlled trials. More high-quality and large sample RCTs are still needed in the future to clarify whether they have an auxiliary effect on improving the fertility outcomes of DOR. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261438943.

PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Effect of integrin α5β1 on erectile function of spontaneously hypertensive rats].

Gong Hao H, Jiang Rui R

Objective To explore the mechanism by which inhibition of integrin α5β1 in the context of hypertension downregulates the expression of RAS homolog gene family members (RhoA)/Rho-associated kinase (ROCK) signaling proteins in the penile corpus cavernosum tissue, and affects the erectile function of rats.Methods Fifteen 12-week-old spontaneously hypertensive rats (SHR) were randomly divided into the SHR group, SHR+LV-empty group(transfected with empty lentiviral vector) and SHR+LV-siRNA group (transfected with lentivirus carrying siRNA targeting integrin α5β1), with 5 rats in each group. Fifteen 12-week-old normotensive Wistar-Kyoto (WKY) rats were randomly divided into the WKY rat group, WKY+LV-empty group (transfected with empty lentiviral vector) and WKY+LV-siRNA group (transfected with lentivirus carrying siRNA targeting integrin α5β1), with 5 rats in each group. In the WKY group and SHR group, 20 μL of normal saline was injected into the middle part of the penile corpus cavernosum. While in the SHR + LV-empty group and WKY + LV-empty group, 20 μL of empty lentiviral vector (titer 1×108 TU/mL) was injected into the middle part of the penile corpus cavernosum. In the SHR+LV-siRNA group and WKY+LV-siRNA group, 20 μL of lentivirus carrying integrin α5β1 interference (titer 1×108 TU/mL) was injected into the middle part of the penile corpus cavernosum. One week after transfection, the body weight, levels of serum testosterone, ratio of the maximum intracavernous pressure to the mean arterial pressure (ICPmax/MAP) of rats in each group, the expression of integrin α5β1, FAK, ROCK1, ROCK2, and eNOS in penile corpus cavernosum, as well as the content of nitric oxide (NO) were measured. Results There was no statistically significant difference in body weight and serum testosterone levels among the rats in each group (P> 0.05). Compared with the WKY group, the ICPmax/MAP in the SHR group was significantly lower (P< 0.05), and the expressions of integrin α5β1, FAK, ROCK1, and ROCK2 in the penile corpus cavernosum of the SHR group were significantly higher (P<0.05), while the expression of eNOS and the content of NO decreased significantly (P<0.05). After successful transfection with integrin α5β1 interfering lentivirus, compared with the WKY+LV-empty group, there were no statistically significant differences in ICPmax/MAP, eNOS expression in the penile corpus cavernosum, and NO content in the WKY+LV-siRNA group (P>0.05), but the expressions of integrin α5β1, FAK, ROCK1, and ROCK2 were significantly decreased (P<0.05). Compared with the SHR+LV-empty group, the ICPmax/MAP in the SHR+LV-siRNA group was significantly increased (P<0.05). There were no statistically significant differences in eNOS expression in the penile corpus cavernosum and NO content (P>0.05). While the expressions of integrin α5β1, FAK, ROCK1, and ROCK2 were significantly decreased (P< 0.05). Conclusion Hypertension upregulates the expression of integrin α5β1 in the penile corpus cavernosum, activates the RhoA/ROCK signaling pathway, and leads to penile erectile dysfunction. Inhibiting the expression of integrin α5β1 in penile cavernous tissue of SHRs downregulates the RhoA/ROCK signaling pathway and improves the erectile function of SHRs.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about testosterone